Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8155897 | 0.76 | DGAT1 (0.48) | DGAT1MEN1KMT2A | |
| SCHEMBL1714208 | 0.74 | DGAT1 (0.50) | DGAT1CA14CTSKALDH1A1SMN1; SMN2 | |
| SCHEMBL4463196 | 0.73 | KDM4C (0.42) | CA14CA2ALDH1A1POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28000852 | 0.72 | DGAT1 (0.48) | DGAT1CA14CTSKSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4469009 | 0.71 | KDM4C (0.41) | CA14CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4469005 | 0.71 | CA2 (0.40) | CA14CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL20882727 | 0.71 | DGAT1 (0.43) | DGAT1CA14CA2ALDH1A1MEN1 | |
| SCHEMBL10013884 | 0.71 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL18334532 | 0.71 | CA14 (0.46) | DGAT1CA14CA2CTSKALDH1A1 | |
| SCHEMBL16976213 | 0.70 | DGAT1 (0.52) | DGAT1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4056580-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-14 | — | — | EP | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | DGAT1 3349/4885CA14 1972/4885CA2 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.